Price
Target price
€1.82
€1.82
3.880%
0.068
3.880%
€4.16
17:13 / Tradegate
WKN: A3C4ZC / Symbol: XERS / Name: Xeris Biopharma / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Xeris Biopharma Holdings Inc. Stock
A very strong showing by Xeris Biopharma Holdings Inc. today, with an increase of €0.068 (3.880%) compared to yesterday's price.
Our community is currently high on Xeris Biopharma Holdings Inc. with 5 Buy predictions and 0 Sell predictions.
With a target price of 4 € there is potential for a 119.78% increase which would mean more than doubling the current price of 1.82 € for Xeris Biopharma Holdings Inc..
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
S********** s********
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | 3.880% | -0.170% | -2.389% | -33.947% | -18.657% | -37.915% | - |
| Ardelyx Inc. | -1.950% | -16.636% | 8.504% | 81.259% | 24.498% | 28.500% | - |
| Evolus Inc | - | -3.333% | 4.505% | 26.087% | 28.177% | 57.823% | - |
| Salarius Pharmaceuticals Inc. | -2.360% | 1.471% | 1.471% | -62.703% | -25.405% | -98.319% | -99.992% |
Comments
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $3.00 price target on the stock, down previously from $4.00.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $5.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its price target lowered by analysts at Piper Sandler from $5.00 to $4.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat